Eiger BioPharmaceuticals, Inc. (EIGR)
(Delayed Data from NSDQ)
$10.50 USD
-0.22 (-2.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.50 USD
-0.22 (-2.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -12.73% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Incyte (INCY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 28.17% and 94.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Deciphera Pharmaceuticals (DCPH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
Eiger BioPharmaceuticals (EIGR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 3.03% and 30.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Eiger BioPharma (EIGR)? Wall Street Analysts Think 493%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 493% in Eiger BioPharma (EIGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Eagle Pharmaceuticals (EGRX) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -12.07% and 19.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -5.56% and 29.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Eiger BioPharmaceuticals (EIGR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -275.76% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Eiger (EIGR) Gets FDA Approval for Zokinvyin Rare Diseases
by Zacks Equity Research
Eiger (EIGR) gets FDA approval for Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.
Eiger (EIGR) Up on Positive Results From Coronavirus Study
by Zacks Equity Research
Eiger (EIGR) gains on positive results from the ILIAD study on peginterferon lambda-1a (lambda) in outpatients with mild-to-moderate COVID-19.
Eiger Down on Disappointing Results From Coronavirus Study
by Zacks Equity Research
Eiger (EIGR) declines on disappointing study results on candidate, peginterferon lambda-1a (lambda), in outpatients with mild and uncomplicated COVID-19.
Implied Volatility Surging for Eiger BioPharmaceuticals (EIGR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Eiger BioPharmaceuticals (EIGR) stock based on the movements in the options market lately.
Eiger BioPharmaceuticals (EIGR) Catches Eye: Stock Jumps 8.6%
by Zacks Equity Research
Eiger BioPharmaceuticals (EIGR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Eiger BioPharma (EIGR) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Eiger BioPharma (EIGR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Eiger BioPharmaceuticals (EIGR) Stock Might be a Great Pick
by Zacks Equity Research
Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now?
by Zacks Equity Research
Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Eiger BioPharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Eiger BioPharmaceuticals
Eiger Completes NDA Submission of Progeria Drug Lonafarnib
by Zacks Equity Research
Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.
What Makes Eiger BioPharma (EIGR) a New Buy Stock
by Zacks Equity Research
Eiger BioPharma (EIGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Eiger BioPharma (EIGR) a New Buy Stock
by Zacks Equity Research
Eiger BioPharma (EIGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Eiger BioPharmaceuticals (EIGR) Enters Oversold Territory
by Zacks Equity Research
Eiger BioPharmaceuticals, Inc. (EIGR) has been on a bit of a cold streak lately
Eiger BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Eiger BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?